The transcriptional repressor Blimp-1 promotes Th2 development and lung inflammatory disease in a house dust mite induced model of allergic asthma

Abstract

Asthma is a T cell-mediated chronic inflammatory lung disease that is thought of as a type 2/Th2 disease, yet precisely how Th2 cell development in the lung is initiated is unknown. Blimp-1 is a transcriptional repressor that regulates effector T cell responses to constrain T cell-mediated autoimmunity. We describe Blimp-1 as an unexpected regulator of allergen-induced airway inflammation that is critical to promote Th2 cell development in the lung and subsequent airway inflammation. Using a house dust mite (HDM) antigen model to drive allergic lung disease, we show that the T cell specific absence of Blimp-1 leads to reduced lung inflammation, a significant decrease in eosinophil recruitment to the lung tissue, and a near absence of Th2 cells in the lung. Intriguingly, Th1 and Th17 responses are intact, suggesting Blimp-1 is specifically required for Th2 differentiation in this model. Furthermore, despite a lack of Th2 cells in the lung, IgE responses are intact, dissociating IL-4-mediated antibody driven responses from Th2 cells in the lung. Bcl6 expression is increased in both the draining lymph node and lung and using T cell specific Bcl6 and Blimp-1 double deficient mice, we find that Th2 cells are restored when Bcl6 is deleted in addition to Blimp-1. Bcl6 is a potent repressor of GATA3, suggesting Blimp-1 acts to indirectly promote GATA3 expression by suppression of Bcl6. Furthermore, we show that STAT3 signaling in T cells is responsible to upregulate Blimp-1 and subsequent Th2 development, implicating this pathway as a possible therapeutic target. Taken together, our data suggests Blimp-1 plays an unexpected and context-dependent role in allergic lung inflammation to promote Th2 cell differentiation and subsequent lung disease.